The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

The infusion rate should be reduced by 50% in case of nonserious infusion reactions In patients who develop serious infusion reactions, cetuximab should be discontinued immediately and permanently ...